Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
August 08 2022 - 6:30AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for allergy, opioid overdose, respiratory and inflammatory
disease, today announced that it will host an investor conference
call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to
discuss its financial and operating results for the second quarter
2022 as well as provide a corporate update. The company’s press
release concerning its second quarter 2022 financial results is
expected to be available after 1 p.m. Pacific Time on August 10,
2022, and on its website.
Event: Adamis Pharmaceuticals Second Quarter 2022 Financial
Results Conference Call Date: Wednesday, August 10,
2022 Time: 1:30 p.m. PT (4:30 p.m. ET) U.S. Dial-in (Toll
Free): 1-877-423-9813 Toll/International Dial-in:
1-201-689-8573 Conference ID: 13731678
David J. Marguglio, President and CEO of Adamis, will host the
call along with other members of the management team. The call is
open to the public and will provide an update on recent
developments, events that have taken place during the year, and
certain goals for future periods. Forward-looking statements
concerning expectations regarding future company performance may be
made during the conference call.
A live audio webcast of the conference call will also be
available via this link, with a replay available shortly after the
live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI® (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. The Company’s ZIMHI™ (naloxone)
Injection product is approved for the treatment of opioid overdose.
Tempol is in development for the treatment of patients with
COVID-19 and a Phase 2/3 clinical trial is underway. For additional
information about Adamis Pharmaceuticals, please visit our website
and follow us on Twitter and LinkedIn.
Contact:
Adamis Investor RelationsRobert Uhl Managing
Director ICR
Westwicke619.228.5886 robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2024 to May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2023 to May 2024